CA2894182A1 - Peptide therapeutics and methods for using same - Google Patents

Peptide therapeutics and methods for using same Download PDF

Info

Publication number
CA2894182A1
CA2894182A1 CA2894182A CA2894182A CA2894182A1 CA 2894182 A1 CA2894182 A1 CA 2894182A1 CA 2894182 A CA2894182 A CA 2894182A CA 2894182 A CA2894182 A CA 2894182A CA 2894182 A1 CA2894182 A1 CA 2894182A1
Authority
CA
Canada
Prior art keywords
arg
subject
lys
phe
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2894182A
Other languages
English (en)
French (fr)
Inventor
D. Travis WILSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Corp
Original Assignee
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc filed Critical Stealth Peptides International Inc
Publication of CA2894182A1 publication Critical patent/CA2894182A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
CA2894182A 2012-12-06 2013-04-11 Peptide therapeutics and methods for using same Abandoned CA2894182A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734293P 2012-12-06 2012-12-06
US61/734,293 2012-12-06
PCT/US2013/036214 WO2014088631A1 (en) 2012-12-06 2013-04-11 Peptide therapeutics and methods for using same

Publications (1)

Publication Number Publication Date
CA2894182A1 true CA2894182A1 (en) 2014-06-12

Family

ID=49549068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2894182A Abandoned CA2894182A1 (en) 2012-12-06 2013-04-11 Peptide therapeutics and methods for using same

Country Status (7)

Country Link
US (3) US20130303436A1 (https=)
EP (3) EP3459598A1 (https=)
JP (3) JP2016506391A (https=)
CN (1) CN104994912A (https=)
CA (1) CA2894182A1 (https=)
HK (1) HK1215934A1 (https=)
WO (1) WO2014088631A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
WO2015057315A1 (en) * 2013-09-04 2015-04-23 Kelly Joseph Michael Lawless Methods and systems for the detection of disease
US9895410B2 (en) * 2013-12-12 2018-02-20 Cornell University Methods for preventing and treating oral cancers
CN105849123A (zh) * 2013-12-13 2016-08-10 免疫医疗有限公司 蛋白酶抗性肽
US20170007663A1 (en) * 2013-12-16 2017-01-12 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
US10221213B2 (en) 2013-12-27 2019-03-05 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides
JP2017512762A (ja) * 2014-03-03 2017-05-25 ステルス バイオセラピューティックス コープ 薬学的に妥当な芳香族カチオン性ペプチド及びその生成方法
WO2015183995A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183985A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including naphthoquinones and uses thereof
EP3502132A1 (en) * 2014-05-28 2019-06-26 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
WO2015183963A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
US10627392B2 (en) 2014-06-17 2020-04-21 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
CA2958585C (en) * 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
BR112017009584A2 (pt) 2014-11-07 2017-12-26 Nacuity Pharmaceuticals Inc tratamento de retinite pigmentosa com n-acetilcisteína amida
US20170315135A1 (en) * 2014-11-11 2017-11-02 The Johns Hopkins University Biomarkers useful in the treatment of subjects having retinits pigmentosa
US11268964B2 (en) * 2014-11-11 2022-03-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
EP3265109B1 (en) 2015-03-06 2020-10-21 Stealth BioTherapeutics Corp Processes for preparing pharmaceutically relevant peptides
WO2016190852A1 (en) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
WO2016195663A1 (en) * 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
CN108697768B (zh) * 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
CN105987840B (zh) * 2016-06-03 2018-09-28 浙江世纪康大医疗科技股份有限公司 一种柠檬酸抗原修复液
CN105987839B (zh) * 2016-06-03 2018-09-28 浙江世纪康大医疗科技股份有限公司 一种edta-柠檬酸抗原修复液
JP2019517586A (ja) * 2016-06-03 2019-06-24 ジェイティー ファーマスーティカルズ、インク． カッパオピオイド受容体アゴニストの持続放出組成物
CN107042067B (zh) * 2017-05-24 2019-11-08 天津大学 聚硅氧烷-金属有机框架材料杂化渗透蒸发复合膜及其制备与应用
CA3067890A1 (en) * 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
EP3443980A1 (en) * 2017-08-15 2019-02-20 Ciliocure Limited Compound for the treatment of patients with leptin-resistant obesity, bardet-biedl syndrome and other ciliopathies
US11548851B2 (en) 2017-09-20 2023-01-10 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US11091433B2 (en) 2017-09-20 2021-08-17 Nacuity Pharmaceutials, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
CN111386255B (zh) 2017-09-20 2021-11-23 纳崔泰制药有限公司 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
WO2019201333A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
EP3908341A4 (en) 2019-01-11 2022-03-02 NaCuity Pharmaceuticals, Inc. TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
US12458608B2 (en) 2019-01-11 2025-11-04 Nacuity Pharmaceuticals, Inc. N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
AU2020316449B2 (en) * 2019-07-24 2026-02-05 Stealth Biotherapeutics Inc. The peptidomimetic compound (R)-2-amino-N-((S)-L-(((S)-5-amino-L-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases
WO2022006470A1 (en) 2020-07-01 2022-01-06 Vanderbilt University Methods of treatment for a kidney disease
KR102503914B1 (ko) * 2020-09-01 2023-02-24 인제대학교 산학협력단 황반변성 세포모델의 제조방법
US20230381281A1 (en) * 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
CN112618966B (zh) * 2020-12-18 2023-07-28 北京宏强富瑞技术有限公司 一种多波长激光针刺仪
CN113421648B (zh) * 2021-06-21 2024-04-23 中国科学院北京基因组研究所(国家生物信息中心) 一种用于预测射血分数保留型心衰风险的模型
CN113588375B (zh) * 2021-08-20 2023-09-29 中科光华(西安)智能生物科技有限公司 一种高稳定性骨及骨肿瘤组织微阵列芯片及其制备方法
CN116262134A (zh) * 2021-12-15 2023-06-16 联邦生物科技(珠海横琴)有限公司 一种稳定的多剂量给药的glp-1受体激动剂的制剂及其制备方法和应用
CN114480449A (zh) * 2022-03-17 2022-05-13 天津医科大学总医院 布拉氏酵母菌CNCMI-745衍生蛋白Trx2及其在制备防治腹泻药物中的应用
CN114949184A (zh) * 2022-05-13 2022-08-30 华中科技大学同济医学院附属同济医院 Glp-1代谢物在制备减轻急性肾损伤药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2001066140A1 (en) 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
AU2002256092C1 (en) 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
ATE408414T1 (de) * 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP1701731A4 (en) 2003-12-12 2009-08-05 Einstein Coll Med GLP-1 (9-36) METHOD AND COMPOSITIONS
US20090202497A1 (en) * 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
AU2008303922A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe alone or in combination with the peptide Gly-Ard-Gly-Asp-Asn-Pro-OH as a therapeutic agent
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
CN102614514B (zh) * 2011-01-26 2014-12-10 王永祥 Glp-1受体激动剂用于治疗疼痛

Also Published As

Publication number Publication date
JP2018021033A (ja) 2018-02-08
US20130303436A1 (en) 2013-11-14
EP3287172A1 (en) 2018-02-28
JP2019069942A (ja) 2019-05-09
CN104994912A (zh) 2015-10-21
EP2928562A1 (en) 2015-10-14
US20180344814A1 (en) 2018-12-06
EP3459598A1 (en) 2019-03-27
HK1215934A1 (zh) 2016-09-30
WO2014088631A1 (en) 2014-06-12
US20160101158A1 (en) 2016-04-14
JP2016506391A (ja) 2016-03-03
EP2928562A4 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
US10293020B2 (en) Peptide therapeutics and methods for using same
US20180344814A1 (en) Peptide therapeutics and methods for using same
US20190023738A1 (en) Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
US11141456B2 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
US20160199437A1 (en) Therapeutic compositions including iron chelators and uses thereof
WO2015183963A2 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2016200364A1 (en) THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
WO2016195663A1 (en) Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
US20170182117A1 (en) Therapeutic compositions including therapeutic small molecules and uses thereof
US20180042983A1 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof, and methods of using the same
US20180354991A1 (en) Therapeutic compositions including gramicidin s peptidyl conjugates or imidazole-substituted fatty acids, variants thereof and uses thereof
US20240108740A1 (en) Therapeutic compositions including spn10 and uses thereof
WO2015183984A2 (en) Therapeutic compositions including tocopherol and uses thereof
WO2016144352A2 (en) Therapeutic compositions including acrylamido compounds or phenyl-substituted maleimide compounds, variants thereof and methods of using the same
US20160279255A1 (en) THERAPEUTIC COMPOSITIONS INCLUDING MODULATORS OF deltaPKC AND/OR epsilonPKC, AND USES THEREOF
WO2015183985A2 (en) Therapeutic compositions including naphthoquinones and uses thereof
WO2016190852A1 (en) Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
WO2015183970A1 (en) Therapeutic compositions including flavonoid and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180411

FZDE Discontinued

Effective date: 20210831